Vitamin K2 switches on proteins that decide where the body deposits calcium. Firmest findings: slowed bone density loss at the spine after menopause, and lower average blood sugar in type 2 diabetes. Fracture and artery evidence is split. Two supplement forms differ in dose and are not interchangeable. It opposes older blood-thinning drugs at amounts far below one capsule. (Full Review)

Protocol

Standard MK-7 protocol

90–180 µg once daily

With a fat-containing meal, continued indefinitely. The range used in the trials reporting bone density and arterial stiffness effects.

Higher-dose MK-7 protocol

360 µg once daily

Reserved for established calcification or documented poor vitamin K status; no demonstrated advantage in healthy adults.

Japanese high-dose MK-4 protocol

45 mg daily

Usually split as 15 mg three times with meals; the licensed osteoporosis regimen in Japan, a pharmaceutical dose, not a nutritional one.

Time to effect

Slowed loss of bone mineral density

1–3 years

Bone density and arterial stiffness changes took one to three years to separate from placebo; nothing measurable happens on a scale of weeks.

Improved glycaemic control in type 2 diabetes

12 weeks

Fasting glucose and HbA1c fell over 12 weeks; none of the trials ran past six months.

Reduced fracture incidence

2 years

Fewer fractures on high-dose MK-4 appeared over 24 months; established in Japanese cohorts and unconfirmed elsewhere.

Benefits

High: Slowed loss of bone mineral density; improved glycaemic control in type 2 diabetes; reduced fracture incidence

Medium: Reduced arterial stiffness in postmenopausal women; lower cardiovascular mortality with higher dietary menaquinone intake; reduced frequency and severity of nocturnal leg cramps

Low: Slowed coronary artery calcification; reduced liver cancer recurrence and mortality

Speculative: Increased testosterone production; improved carboxylation of extra-hepatic vitamin K proteins

Contraindications

Vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon) at any INR target of 2.0 or above, unless an anticoagulation clinic manages the combination explicitly

Documented late-onset anaphylactic reaction to natto or poly-gamma-glutamic acid, for fermentation-derived MK-7 specifically

Child-Pugh Class C cirrhosis or untreated cholestasis

Newborns

Key Interactions

Bile acid sequestrants (cholestyramine, colestipol, colesevelam)

Fat absorption blockers (orlistat, mineral oil)

Broad-spectrum antibiotics (cefoperazone, cefotetan, rifampin, prolonged courses of any class)

High-dose vitamin E (above roughly 800 IU daily)

Vitamin D and calcium supplements (additive by design, not adverse)

Statins (atorvastatin, rosuvastatin, simvastatin), theoretical caution

Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran): no interaction

Risk & Side Effects

High: Loss of anticoagulant control on vitamin K antagonists

Medium: Gastrointestinal symptoms; small rise in serum calcium in dialysis populations

Low: Hypersensitivity to fermentation-derived preparations

Speculative: Increased active calcification signal on molecular imaging; thrombosis from enhanced clotting factor carboxylation

Monitoring

Marker	Target	Why
INR (international normalized ratio)	1.0 if not anticoagulated; unchanged from the clinic target if anticoagulated	Detects the one serious interaction
Prothrombin time	11–13 seconds	Confirms clotting factor carboxylation is intact
Dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP)	Below 300–500 pmol/L	The direct read-out of extra-hepatic vitamin K sufficiency
Undercarboxylated osteocalcin (ucOC) as a fraction of total osteocalcin	Below 20%	Bone-specific vitamin K sufficiency
Serum calcium (albumin-corrected)	2.20–2.45 mmol/L (8.8–9.8 mg/dL)	Detects the small rise reported in kidney disease
25-hydroxyvitamin D	30–50 ng/mL (75–125 nmol/L)	Vitamin D drives synthesis of the proteins vitamin K2 activates
Estimated glomerular filtration rate (eGFR)	Above 60 mL/min/1.73 m²	Identifies who carries both the largest deficit and the calcium-rise risk
Bone mineral density (DXA T-score)	Above −1.0	The endpoint the bone evidence is built on
Coronary artery calcium score	0 Agatston units	The endpoint the vascular evidence is built on
HbA1c (glycated haemoglobin)	Below 5.4%	Where the metabolic claim would show up

Cadence: Where a vitamin K antagonist is involved, INR at 1 and 4 weeks after any change, then the clinic's usual interval. Serum calcium and vitamin D at 3 months, then every 6 to 12 months. Bone density and calcium scoring are not usefully repeated inside 2 years.

Qualitative Assessment

Qualitative markers are weak for this intervention and are not reliable indicators
Unexplained bruising or bleeding at the gums, which points to over-anticoagulation rather than to the supplement
Nausea, abdominal discomfort, or loose stools in the first weeks, which usually resolve when the dose moves to a fatty meal
Dental calculus (hardened plaque on the teeth) and tooth sensitivity, occasionally reported anecdotally and without trial support
Absence of any perceptible change, which is the expected experience and not evidence the protocol has failed

Vitamin K2 for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment